The present invention relates to cell lines that produce ligands that bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms cell lines produce ligands that bind to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs), single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.

 
Web www.patentalert.com

< Optical feedthrough assembly for use in implantable medical device

> Distinguishing non-resonant four-wave-mixing noise in coherent stokes and anti-stokes Raman scattering

> Transdiscal administration of cycline compounds

~ 00530